- Home
- CLDX vs XNCR Comparison
CLDX vs XNCR Comparison
Compare CLDX & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLDX
- XNCR
- Stock Information
- Founded
- CLDX 1983
- XNCR 1997
- Country
- CLDX United States
- XNCR United States
- Employees
- CLDX N/A
- XNCR N/A
- Industry
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- XNCR Biotechnology: Pharmaceutical Preparations
- Sector
- CLDX Health Care
- XNCR Health Care
- Exchange
- CLDX Nasdaq
- XNCR Nasdaq
- Market Cap
- CLDX 1.6B
- XNCR 1.7B
- IPO Year
- CLDX 2008
- XNCR 2013
- Fundamental
- Price
- CLDX $23.78
- XNCR $19.24
- Analyst Decision
- CLDX Buy
- XNCR Strong Buy
- Analyst Count
- CLDX 7
- XNCR 9
- Target Price
- CLDX $64.83
- XNCR $36.33
- AVG Volume (30 Days)
- CLDX 1.1M
- XNCR 766.2K
- Earning Date
- CLDX 02-24-2025
- XNCR 02-25-2025
- Dividend Yield
- CLDX N/A
- XNCR N/A
- EPS Growth
- CLDX N/A
- XNCR N/A
- EPS
- CLDX N/A
- XNCR N/A
- Revenue
- CLDX $9,976,000.00
- XNCR $85,164,000.00
- Revenue This Year
- CLDX N/A
- XNCR N/A
- Revenue Next Year
- CLDX N/A
- XNCR $80.86
- P/E Ratio
- CLDX N/A
- XNCR N/A
- Revenue Growth
- CLDX 128.55
- XNCR N/A
- 52 Week Low
- CLDX $22.17
- XNCR $15.31
- 52 Week High
- CLDX $53.18
- XNCR $27.24
- Technical
- Relative Strength Index (RSI)
- CLDX 41.99
- XNCR 29.84
- Support Level
- CLDX $22.17
- XNCR $19.05
- Resistance Level
- CLDX $29.05
- XNCR $24.66
- Average True Range (ATR)
- CLDX 1.57
- XNCR 1.10
- MACD
- CLDX -0.26
- XNCR -0.49
- Stochastic Oscillator
- CLDX 23.40
- XNCR 3.26
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.